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Abstract
Background: Obesity and obesity-related conditions, such as type 2 diabetes, are a major issue for Veteran health.
Veterans Health Administration (VA) researchers and health systems leaders have worked separately and together to
provide more effective weight management programs for Veterans. Although randomized clinical trials are often
considered the gold standard for establishing efficacy of interventions in controlled circumstances, pragmatic clinical
trials (PCTs) provide agility for translation.
Main text: VA researchers and health system leaders collaboratively designed a PCT to compare the Diabetes Prevention
Program (VA-DPP) to usual care (MOVE!®) in promoting weight loss and glycemic control among overweight/obese
Veterans with prediabetes. Together, they navigated the tensions that exist between quality improvement and research
activities, facing challenges but reaping significant rewards. Early findings led to updated national guidance for delivering
obesity treatment in VA.
Short conclusion: Partnered research and the use of PCTs can be powerful strategies for accelerating evidence-based
findings into practice. Collaborative partnerships between researchers and health systems leaders can help enhance and
sustain translation in real-world settings.
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Background
It is essential that researchers work more closely with
health system leaders such as program leaders, policy
makers and other decision makers, to collaboratively de-
sign and conduct studies in a way that translates
evidence-based programs more quickly and effectively
into clinical practice [1–4]. However, differences in per-
spectives and priorities regarding the relative merits of
alternative research questions and the timeline by which
to answer these questions can introduce unique chal-
lenges and tensions. For example, researchers are
rewarded for increasing generalizable knowledge in the
scientific literature, which may take years to produce,
while program leaders must focus on solving more spe-
cific problems and addressing more immediate
organizational needs [5]. Research typically follows a
slower timeline, whereas program changes may occur
more rapidly and/or in real-time. This tension is exacer-
bated by research funding being more available for trad-
itional clinical trials that focus on testing interventions
in relatively controlled circumstances rather than asses-
sing effectiveness and implementation approaches in less
controlled real-world settings [6–9]. Frenk (1992) and
others have described this tension as navigating trade-
offs between scientific excellence (contributing to in-
ternal validity) versus being relevant, responsive, and
timely (contributing to external validity) [4, 5, 10–13]. It
can take an average of 17 years to translate clinical trial
findings broadly into practice [14] and the challenges
and delays are even greater for psychosocial treatments
(e.g., behavioral interventions related to weight manage-
ment) [15].
One of the main challenges for a successful partner-
ship between researchers and health system leaders is
finding a way to simultaneously meet competing needs
of researchers and leaders. The nature of how the
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partnership was created or how it functions can impact
the ability of the partners to navigate challenges. Part-
nerships with equal participation of both partner groups
are better positioned to handle obstacles compared to
partnerships where the organizational partner has a less
equal role [2]. Researchers need time to develop research
questions and study materials, obtain approval from
ethics boards, hire staff, recruit participants and control
the study environment in order to minimize bias. Health
system leaders face enormous demands to get results
implemented quickly to meet organizational demand.
Frenk (1992) describes this as the difference between
political time (perceived as warp speed) and scientific
time (perceived as the pace of the proverbial tortoise)
[5]. Moreover, decision makers often seek answers to
more specific questions than those that traditional
research offers; they are looking for a solution to a
problem within their organization and not necessarily
one that could potentially solve similar problems across
multiple organizations [7]. However, research and deci-
sion makers can work to balance these perspectives by
assessing multiple outcomes that are important to both
partners and within the timeframe needed [8].
Researchers and funders have called for more
pragmatic (or practical) clinical trials that generate
knowledge that is essential to health system leaders who
make real-world decisions based on e.g., cost, feasibility,
fit, and likelihood of generating sufficient value for the
investment [2, 3]. Although randomized controlled
trials have long been considered the gold standard for
evidence-based medicine, pragmatic trials may better
answer these context-specific questions that are
important in real-world implementation [16]. In order
to facilitate pragmatic clinical trials, there must be
existing infrastructure that enables interactions be-
tween researchers and decision makers and also helps
to promote a solid working relationship before embarking
on a research project together [5, 7]. Pragmatic trials focus
on leveraging existing resources whenever possible to
make implementation more feasible. These resources in-
clude the use of existing clinic staff (instead of separate or
newly hired research staff ), usual care comparison (instead
of adding a program for a control group), and integrating
research data into clinical practices (instead of having
outside staff collect and manage data) [17]. Although
pragmatic trials face a number of barriers, including insuf-
ficient funding (since they can be large studies with long
follow-up periods) or sample sizes that are too small to
detect treatment effects (because the unit of analysis is
often at the organizational level e.g., practice-level), these
may be outweighed by tremendous benefits [7].
This paper describes the evolution of a partnership be-
tween Veterans Health Administration (VHA) Diabetes
Quality Enhancement Research Initiative (QUERI) center
researchers and national health system leaders within the
VHA National Center for Health Promotion and Disease
Prevention (NCP), a center that has responsibility for
developing policies to promote prevention in VHA, in-
cluding weight management services. This collaborative
partnership, which spans over 5 years and five research
projects, has culminated most recently in a pragmatic
clinical evaluation from which preliminary results were
used to inform system-wide changes within the delivery of
VA weight management services. Overall, this work pro-
vides a case illustration for how rapid, responsive, and
relevant research findings [3] can be generated through a
productive partnership between researchers and health
system leaders. In addition to demonstrating the power of
partnered research, this paper describes how to overcome
challenges in conducting more pragmatic research within
a clinical setting.
A short history of weight management in the VA
As policy makers, NCP oversees health promotion
within the VA, which spans guidance for clinical prac-
tices to providing programs and resources, including
obesity prevention and weight management services.
Over the past decade, NCP has faced a high priority
need to address the growing obesity epidemic within
VHA since 75% of Veterans using VA medical services
were considered overweight or obese [18]. In response,
NCP developed the evidence-based MOVE!® Weight
Management Program for Veterans (hereafter referred
to as “MOVE!”), which has been implemented at 155 VA
medical centers and 872 community-based outpatient
clinics across the nation [18]. Implementation of MOVE!
varies widely across sites, although in general, program
components include an initial assessment and weekly
group sessions for 6 to 10 weeks [19]. The group
sessions are intended to provide self-management
support to help patients lose weight.
An evolving research-organizational stakeholder
partnership
In 2011, executive leaders in VA directed NCP to
disseminate the Diabetes Prevention Program [20] in VA
facilities within a very short timeframe. This request was
motivated by the success of the Diabetes Prevention
Program (DPP) which showed that compared to placebo,
an intensive lifestyle change program was associated
with a 58% reduction in type 2 diabetes incidence
among individuals with pre-diabetes over 3 years of
follow-up [20]. Long-term observational follow-up
studies showed that these benefits were also sustained
for up to 15 years, although results have been less
dramatic in real-world settings where degree of im-
plementation may vary [21–25].
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NCP reached out to VA QUERI researchers to help
conduct and evaluate a clinical demonstration of a
group-based version of the DPP (VA-DPP) at three
pilot sites in the VA. The VA QUERI researchers had
experience and interest in developing and evaluating
programs related to weight loss and chronic disease
self-management. NCP leaders have collaborated with
these researchers several times since the early days of
the MOVE! program [26–29].
Because of this long-standing partnership and mutual
trust built over time, the partnered team successfully ne-
gotiated challenging logistics to launch the VA-DPP
demonstration only 10 months later. Since research
partners often bring different perspectives in how to
approach the project, the existing trusting relationship
was a key factor in negotiating these differences to rap-
idly proceed with the VA-DPP trial [30]. (see Table 1)
The challenges included funding, the short timeframe,
and the need to navigate regulatory requirements
governing clinical quality improvement (QI) initiative
and research activities [31].
Navigating trade-offs
Study design
NCP leaders funded a clinical demonstration of the VA-
DPP at three medical centers. This initiative was deemed
a clinical QI project, which meant that implementation
of the VA-DPP could proceed without the additional
time and work needed to obtain institutional review
board (IRB) approval; with pressure from high-level
leaders to launch the project quickly, this was a key
“win.” However, the researchers wanted to collect
additional measures (e.g., motivation, goal setting) and
link this information to administrative data (including
clinical outcomes of change in weight and blood glu-
cose) to better explain and potentially predict outcomes.
To do this, research funding and IRB approval were
needed for each study site without delaying the launch
of the clinical program. Another crucial decision was the
number of study sites: NCP leaders wanted to conduct
the evaluation at three sites and identify three additional
sites as controls. The research team was concerned
about the ability to attribute any potential differences in
outcomes to the program (DPP vs MOVE!) rather than
significant differences between sites. On the other hand,
having both the VA-DPP and MOVE! Conducted at the
same site introduced other potential biases (e.g.,
spillover effect). The teams weighed the options and
together, decided that the latter was a stronger design.
Both MOVE! And the VA-DPP were delivered in-
person at three VA Medical Centers; the main
differences were that the VA-DPP convened closed
groups (participants progressed through the program
in cohorts; no new patients could join after the
program started), all sessions were led by a consistent
facilitator, and VA-DPP was designed to deliver more
Table 1 Key decision points for partnered research design [30]
Design element Operational considerations Researcher considerations Compromise
Study population
Patient screening No systematic pre-diabetes
screening in place, just weight
management referral system
Need to screen patients at
risk for pre-diabetes
Use weight management referral system and add
pre-diabetes screening
Study design




Answer both; program implemented on more rapid
timeline and preliminary data used to make
operational decisions
Group assignment By site; pre-post Randomization Systematic assignment










Ethics review IRB and informed consent
not necessary for QI
IRB and informed consent
required for research
IRB and informed consent for evaluation components
only
Funding sources Clinical funds for QI components Research funds for
evaluation
components
Maintain separate funding sources for QI vs research;
funding sources were pieced together over time
Outcome assessment
Timeline Need for rapid results Need time for study design,
proposal review, and data
analysis
Provide preliminary results prior to final outcomes
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sessions (16 over first 6 months vs 8–10 over first
6 months). Further details about both programs are
published elsewhere [32, 33].
The VA-DPP was integrated into existing clinical pro-
cesses to the extent possible. For example, the VA-DPP
relied on existing MOVE! referral infrastructure and
processes to recruit patients. Inclusion criteria also relied
on weights and hemoglobin (HbA1c) test results that
were documented as part of routine clinical care.
However, the existing referral infrastructure was based
on screening patients by body mass index, so each site
had to add a procedure to also screen patients for pre-
diabetes to determine study eligibility [32, 34–36]. This
process was more complicated and time-consuming than
expected [32, 34–36]. Each of the three sites had to
design, often negotiate, and integrate a process to deter-
mine diabetes status (normal glycemic status, prediabe-
tes, or diabetes). Compounding this challenge, the study
sites experienced lower than expected numbers of
referrals for weight management [37], on which recrui-
ting for VA-DPP relied.
The three VA-DPP demonstration sites were se-
lected to diversify the racial and ethnic mix of pa-
tients as well as geographic location. Exclusion
criteria were minimal to allow for a more heteroge-
neous study population that reflected a typical real-
world patient population. Within the setting and ob-
jectives of this evaluation, a randomized controlled
clinical trial provides strong internal validity, avoiding
potential bias that may occur with other assignment
approaches. However, NCP leaders and local staff
deemed randomization infeasible, as is often the case
within naturalistic clinical practice settings. The teams
collaboratively designed an approach to systematically
assign patients to the VA-DPP vs. MOVE! (e.g., the
first 20 referred eligible patients were assigned to VA-
DPP and the second 20 patients assigned to MOVE!)
[34]. Systematic assignment was a simple approach
that clinical staff could use to divide eligible partici-
pants into two study arms. However, there were
significant differences in race/ethnicity between the
two assignments (p = 0.04): a higher proportion of
Hispanic participants (8.8% vs 3.3%) and lower pro-
portions of non-Hispanic black (36.3% vs 43.6%) and
non-Hispanic white (39.8% vs 44.7%) participants
were assigned MOVE! [35]. It is impossible to know
whether randomization would have mitigated this
imbalance. Because the VA-DPP demonstration was
deemed a clinical QI initiative, written informed
consent was not required for participation in the
either VA-DPP or MOVE!. However, written, in-
formed consent was required for participation in
questionnaires and interviews conducted as a part of
the multi-faceted evaluation.
Funding
Although clinical funding from NCP was used to
conduct the implementation and day-to-day activities re-
quired for the actual demonstration of VA-DPP, research
funding was needed to administer surveys to participants
and to link survey data to clinical outcomes data (e.g.,
change in weight) for the purposes of evaluation. Each
component of the overall project was individually
deemed as being QI or research (the detailed list is pub-
lished elsewhere) [33]; the research team had to obtain
approval to use QI elements for the research analysis
component of the project. The research evaluation was
integrated with the QI project as a Hybrid Type III
pragmatic effectiveness-implementation trial; i.e., the
evaluation had a primary aim of studying a strategy for
implementing VA-DPP and secondary aim of assessing
clinical effectiveness [38]. Due to pressure to launch the
VA-DPP project quickly, clinical activities were already
underway when the research team submitted a proposal
to conduct the evaluation under a “rapid response,”
peer-reviewed, 1-year pilot grant mechanism in the VA
[similar to a National Institutes of Health (NIH) R21
grant] to collect baseline survey data. Fortunately, the
pilot grant was approved on the first submission, which
enabled the research team to begin collecting baseline
data just as enrollment into the demonstration started.
The research team then submitted a large proposal for a
multi-year grant mechanism (similar to an NIH R01
implementation grant) grant to fund the remaining
2 years of work required to collect follow-up data and
conduct analyses. This too, fortunately, was reviewed
and approved in its first submission.
Clinical vs research activities
As a clinical QI project, funded by clinical dollars, the VA-
DPP demonstration project did not require approval by
the IRB and as previously mentioned, written informed
consent was not required to participate in either clinical
program. Specifically, the delivery of the VA-DPP and
MOVE! sessions, collection of weights and HbA1c were
all part of the QI clinical process. However, evaluation of
these data was considered research and required approvals
by five IRBs at five different institutions: the three VA-
DPP demonstration sites, the research coordinating site,
and a research collaboration site. The IRBs were asked to
approve use of VA-DPP QI data for the research
evaluation. Written informed consent and signed HIPAA
authorization were required to administer the question-
naires as well as to access and link clinical data (e.g.,
weights) with the questionnaire responses. The research
team and the operational partners had to carefully
navigate the complexities of determining whether ac-
tivities were QI (related to the VA-DPP clinical dem-
onstration) versus research (related to accompanying
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evaluation) throughout the project in order to ensure
compliance to protocols (e.g., reporting adverse
events, addressing missing data).
Timing
As previously mentioned, this pragmatic trial took place
on an accelerated timeline. Midway through the trial,
NCP was under pressure to brief senior leaders and con-
gressional staff on progress and preliminary findings from
the clinical demonstration even though the researchers
were not yet comfortable releasing any findings so early in
the process. The endeavor attracted the attention of the
press, including Minnesota Public Radio (MPR) [39].
Rapid dissemination of preliminary research results can be
a double-edged sword for researchers. While the immedi-
ate attention on research findings by high-level leaders
and the press helped to rapidly and broadly publicize the
initiative, there is the risk that final outcomes may differ
from preliminary findings. In this case, preliminary find-
ings indicated that participants in the VA-DPP study arm
experienced greater weight loss than those in the control
arm (at 6 months). However, final outcomes indicated that
by 12 months, though trends were in the same direction,
program differences were no longer significant.
Translating findings into clinical practice
The VA-DPP trial findings were rapidly translated to
update guidance to the field to bring the pre-existing
MOVE! program more closely in line with features of
VA-DPP. These included recommendations for a sin-
gle, consistent session leader rather than rotating
topic experts, closing groups to new patients after a
cohort started rather than allowing patients to enter
the program midway through the series, and extend-
ing the program to at least 16 sessions from 12. The
MOVE! program guidelines were updated prior to
completion of the evaluation and before publication
of outcomes. The pragmatic nature of the VA-DPP
trial provided context-sensitive information to help
inform rapid translation of results into clinical set-
tings. This approach differs significantly from the
traditional research process with significant lag times
between trial completion and publication of findings
and then practitioners attempting to translate findings
into their own settings. However, this experience vali-
dates the “integrated, contextual, multilevel research-
practice integration systems approach” described by
Glasgow and Chambers (2012) [3]. (see Table 2) The
evolution of the MOVE! program over the last decade
is a testament to the learning approach taken by NCP
in its pursuit of continuing to improve weight man-
agement programming for Veterans [40].
Benefits and challenges of partnered research for the
health system leader
Having a strong relationship with an experienced and
trusted group of researchers provides clear benefits for
health system leaders, like those within NCP, who are
responsible for developing and implementing policies
and programs within a large national integrated health-
care organization. Program offices often do not have the
staff, funding, or expertise needed to conduct complex
evaluations on their own programs. Researchers are
better prepared to take on the work of obtaining IRB ap-
provals, hiring research assistants, mailing out surveys,
collecting and analyzing data, and other research
activities. Adding the research components complicated
the study because of the additional data collection and
evaluation processes leading to additional time and
effort needed to obtain IRB approvals at five different
sites and annual renewals for each. The researchers also
needed to obtain funding from multiple sources (all with
peer review) for the research components; this work had
to be done in a way that did not interfere with quickly
launching the demonstration project; in fact, the project
was going to launch with or without the research
funding. The research team was focused on minimizing
bias as much as possible during the study. Additionally,
the relative independence of the research group
conducting the evaluation helps provide credibility for
the results of the work. However, external pressure for
findings resulted in system-level changes in guidance
based on preliminary findings; much earlier than the
research team would otherwise have recommended.
Benefits and challenges of partnered research for the
researcher
There are clear advantages to having a health systems
leader as a research partner. NCP provided key support
for the VA-DPP demonstration project, including tech-
nical expertise, insight into their priorities, and funding.
They and the local VA sites also offered use of existing
system infrastructure within which to conduct the VA-
DPP evaluations for program referrals and clinical
outcomes data. Although the research timeline was accel-
erated for the VA-DPP clinical demonstration, researchers
maximized rigor by making careful trade-offs between
strengthening internal versus external validity to inform
study design and data collection. Having an engaged
health system partner established high-level and local
leadership support for the evaluation, which helped to
reduce barriers that potentially could have slowed or
delayed the project. Challenges included the need to
carefully differentiate between research and clinical quality
improvement activities to determine the appropriate
actions, including whether IRB review and approval of
amendments was needed. Although NCP’s contribution of
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clinical funding shows deep support and engagement, it
can also give the impression of undue influence on the
research questions, design and outcomes. Regular com-
munications and transparency were essential to ensuring
that all stakeholders are equal partners while maintaining
independence to ensure scientific rigor. With NCP as an
engaged research partner, there was the clear benefit of a
built-in dissemination channel across VA sites nationally,
which meant that research findings would be translated
quickly with tangible results.
Conclusions/Recommendations for productive
partnerships in research
Partnered research, especially within the context of prag-
matic clinical trials, can help to accelerate translation of
evidence-based interventions into clinical practice. In
our experience, both partners had a shared goal for
research: learning how to evolve weight loss treatment
for Veterans to continue to improve outcomes. The
longstanding relationship between health system leaders
and researchers was built on mutual trust and allowed
each to adjust to conducting quality research yielding
valuable information on a rapid timeline. The shared
history of partnership contributed to establishing shared
goals and clear lines of communication. Conducting
partnered research can be a challenging process but can
result in significant rewards. As research becomes more
collaborative and funders continue to focus on applying
and integrating findings into practice, this collaborative
model of research may become more the norm, espe-
cially as the movement toward creating learning health
systems grows.
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